{"nctId":"NCT00156065","briefTitle":"Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)","startDateStruct":{"date":"2005-09"},"conditions":["Schizophrenia"],"count":187,"armGroups":[{"label":"Haloperidol/Haloperidol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Haloperidol"]},{"label":"Asenapine/Asenapine","type":"EXPERIMENTAL","interventionNames":["Drug: Asenapine"]},{"label":"Placebo/Asenapine","type":"EXPERIMENTAL","interventionNames":["Drug: Asenapine"]}],"interventions":[{"name":"Haloperidol","otherNames":[]},{"name":"Asenapine","otherNames":[]},{"name":"Asenapine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed the short-term 041023 trial (NCT00156104)\n* Continued to meet all demographic and procedural inclusion criteria of the short-term trial upon entry into this long-term extension trial\n* Sign a written informed consent for the 041513 trial.\n* Demonstrated an acceptable degree of compliance with trial medication in the short-term trials in the opinion of the investigator\n\nExclusion Criteria:\n\n* CGI-S (Clinical Global Impressions of Severity of Illness) score of greater than or equal to 6 (severely psychotic)\n* Occurrence(s) of AEs (adverse events) or other clinically significant findings that would prohibit their continuation\n* Met any of exclusion criteria regarding medical/psychiatric status listed in the 041023 short-term trial\n* Met exclusion criteria for medication status in short-term trials except for antidepressants and mood stabilizers.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Loss of Effect Over Time","description":"Loss of effect in subjects who had \\>=30% decrease from baseline in Positive and Negative Syndrome Scale (PANSS) score at the end of the original trial (NCT00156104) preceding the long-term extension.\n\nPANSS is a 30-item clinician-rated instrument for assessing symptoms of schizophrenia. Scores range from 30-210; higher scores indicate greater severity.\n\nLoss of effect = increase in total PANSS \\>=30% from start of current study; subjective worsening of schizophrenia/request for dose increase; Clinical Global Impressions of Severity of Illness score \\>=6; discontinuation for lack of efficacy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Median Survival Time of Effect","description":"Kaplan-Meier estimate of median time to loss of effect in subjects who had \\>=30% decrease from baseline in PANSS score at the end of the original trial (NCT00156104) preceding the long-term extension.\n\nPANSS is a 30-item clinician-rated instrument for assessing symptoms of schizophrenia. Scores range from 30-210; higher scores indicate greater severity.\n\nLoss of effect = increase in total PANSS \\>=30% from start of current study; subjective worsening of schizophrenia/request for dose increase; Clinical Global Impressions of Severity of Illness score \\>=6; discontinuation for lack of efficacy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":50},"commonTop":["INSOMNIA","HEADACHE","ASTHENIA","SCHIZOPHRENIA","PARKINSONISM"]}}}